AbbVie Protocol M21-199- A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety of Atogepant in Pediatric Subjects 6 to 17 Years of Age with Episodic Migraine. Phase III. Feb 2024- Current
AbbVie Protocol M21-201- A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6 to 17 years of age. Phase III. Jan 2024- Current
Supernus Protocol 538P401- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of SPN-538 as a Therapy for the Prevention of Migraine in Subjects Ages 6-11 Years. Phase IV. May 2022-Current
AbbVie Protocol 3110-305-002- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17). Phase III. Sep 2021-Current
AbbVie Protocol 3110-306-002- A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17). Phase III. Sep 2021-Current
TEVA Protocol TV48125-CNS-30084- A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age. Phase Ill. Oct 2020- Current
TEVA Protocol TV48125-CNS30083- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age. Phase Ill. Oct 2020- Current
TEVA Protocol TV48125-CNS30082- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age. Phase Ill. Oct 2020- Current

Eli Lilly TOGETHER Protocol 15Q-US-X003- Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study. A multicenter, double-blind, placebo-controlled study assessing the effectiveness of Galcanezumab as an add-on therapy for Migraine participants on a stable migraine prophylaxis regimen including Botox with or without one other migraine prophylaxis agent (BMPT), who have persistent unmet need. Phase IV. May 2023- Oct 2023
Lundbeck Protocol 19766N- Early Value of Eptinezumab in the Community (EVEC). An exploratory, prospective, randomized, pragmatic open label cohort study to evaluate the comparative effectiveness of eptinezumab in the United States. Aug 2021-Sep 2023
Theranica Protocol TCH-008- A Randomized, Multicenter, Double-Blind, Parallel, Sham-Controlled Study of Non-Invasive Vagal Nerve Stimulation (nVNS) for the Prevention of Migraines. (Premium II) Phase III. Jul 2021-Oct 2022
Allergan Protocol 3101-312-002- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Episodic Migraine (Advance). Phase III. Feb 2021-Nov 2022
Lundbeck Protocol 19386A- Interventional, Randomized, Double-blind, Parallel-group, Placebo-Controlled Delayed-Start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients with Episodic Cluster Headache. Phase III. Dec 2020-Dec 2021
TEVA Protocol TV48125-MH-50039- A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice. Phase IV. Nov 2020-Mar 2023
Novartis- Assessment of Prolonged Safety and tolerability in Migraine Patients in a Long-term Open-Label Study. Phase IV. Clinical Research Coordinator. Jul 2020-Jan 2023
Allergan Protocol 3101-303-002- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine (Progress) Phase III. Mar 2019-Mar 2022
Novartis Protocol CAMG334A2401- A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active-controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (Erenumab qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients. Phase IV. Apr 2019-Nov 2021
Allergan Protocol 3101-309-002- A Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine. Phase III. Apr 2019-Jun 2021
Alder Protocol ALD403-CLIN-015- A Parallel Group Double-Blind Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine. Phase III. Dec 2019-Dec 2020
Theranica Protocol THC006- Efficacy and Safety of Nerivio™, a Remote Electrical Neuromodulation Device, for Acute Treatment of Migraine in People with Chronic Migraine: An Open Label, Single Arm, Multicenter Study. Jan 2020-Aug 2020
Mayo Clinic Protocol 16-001036- Determining the Optimal Treatment Strategy for Patients Who Have Chronic Migraine With Medication Overuse.

Current Studies

Our Staff's Previous Studies